Literature DB >> 1705692

The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions.

Russell K Portenoy1, Kathleen M Foley, Charles E Inturrisi.   

Abstract

In recent years, the observation that the response of patients to opioid drugs may be influenced by properties inherent in the pain or pain syndrome, such as its pathophysiology, has evolved into the belief that certain types of pain, e.g., neuropathic pains, may be unresponsive to these drugs. This concept has important implications for both clinical practice and basic understanding of opioid mechanisms. We critically evaluate opioid responsiveness, particularly as it relates to neuropathic pain, and propose a clinically relevant definition and a paradigm for its investigation. The paradigm is illustrated by analgesic responses to opioid infusion in 28 patients with neuropathic pains and by a detailed presentation of the pharmacokinetic and pharmacodynamic relationships in one of these patients, whose central pain responded promptly to an infusion of hydromorphone. From this analysis, we hypothesize that (1) opioid responsiveness in man can be defined by the degree of analgesia achieved during dose escalation to either intolerable side effects or the occurrence of 'complete' or 'adequate' analgesia; (2) opioid responsiveness is a continuum, rather than a quantal phenomenon; (3) opioid responsiveness is determined by a diverse group of patient characteristics and pain-related factors, as well as drug-selective effects; and (4) a neuropathic mechanism may reduce opioid responsiveness, but does not result in an inherent resistance to these drugs. Given the complexity of factors contributing to opioid responsiveness and the observation that outcome cannot be reliably predicted, opioids should not be withheld on the assumption that pain mechanism, or any other factor, precludes a favorable response. Both the clinical use of opioids and paradigms to investigate opioid responsiveness should include dose escalation to maximally tolerated levels and repeated monitoring of analgesia and other effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1705692     DOI: 10.1016/0304-3959(90)90025-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  58 in total

1.  Use of opioids to treat chronic, noncancer pain.

Authors:  B D Dickinson; R D Altman; N H Nielsen; M A Williams
Journal:  West J Med       Date:  2000-02

Review 2.  Diagnosis and treatment of opiate-resistant pain in advanced AIDS.

Authors:  W C McCormick; R L Schreiner
Journal:  West J Med       Date:  2001-12

Review 3.  Opioids in chronic pain management: is there a significant risk of addiction?

Authors:  G M Aronoff
Journal:  Curr Rev Pain       Date:  2000

Review 4.  Breakthrough pain in cancer patients: new therapeutic approaches to an old challenge.

Authors:  S K Reddy; P Nguyen
Journal:  Curr Rev Pain       Date:  2000

5.  Phantom limbs still a ghostly phenomenon.

Authors:  J Katz
Journal:  CMAJ       Date:  1992-12-01       Impact factor: 8.262

6.  Src family kinases mediate the inhibition of substance P release in the rat spinal cord by μ-opioid receptors and GABA(B) receptors, but not α2 adrenergic receptors.

Authors:  Guohua Zhang; Wenling Chen; Juan Carlos G Marvizón
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

7.  Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats.

Authors:  Junesun Kim; Youngkyung Kim; Suk-Chan Hahm; Young Wook Yoon
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

8.  μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain.

Authors:  W Chen; J A McRoberts; J C G Marvizón
Journal:  Neuroscience       Date:  2014-02-26       Impact factor: 3.590

9.  Complex Regional Pain Syndrome.

Authors:  Ok Yung Chung; Stephen P. Bruehl
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

10.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.